Article citationsMore>>

Li, Q., Li, X., Wang, J., Liu, H., Kwong, J.S., Chen, H., et al. (2019) Diagnosis and Treatment for Hyperuricemia and Gout: A Systematic Review of Clinical Practice Guidelines and Consensus Statements. BMJ Open, 9, e026677.
https://doi.org/10.1136/bmjopen-2018-026677

has been cited by the following article:

• TITLE: The Correlation between the Triglyceride-Glucose Index and the Severity of Non-Alcoholic Fatty Liver Disease in Obese Patients

  AUTHORS: Tian Li, Sheng Pan

  KEYWORDS: Triglyceride-Glucose Index, Non-Alcoholic Fatty Liver Disease, Obesity, Insulin Resistance, Liver Ultrasonography

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.17 No.5, May 20, 2026

  ABSTRACT: Objective: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, particularly among individuals with obesity. This study aimed to investigate the association between the triglyceride-glucose (TyG) index and NAFLD severity in obese patients. Methods: This cross-sectional study included 93 obese adults from Puren Hospital Affiliated to Wuhan University of Science and Technology between January 2022 and December 2023. NAFLD severity was assessed using abdominal ultrasonography and categorized as non-severe (n = 70) or severe (n = 23). The TyG index was calculated as ln [fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2]. Spearman correlation and logistic regression models, and receiver operating characteristic (ROC) analysis were used to examine associations between the TyG index and NAFLD severity. Results: Patients with severe NAFLD had significantly higher TyG indices compared to those with non-severe disease (9.40 vs. 8.83, P = 0.003). The proportion of patients with severe NAFLD was significantly higher in the high TyG group (68.8% vs. 15.6%, P Conclusion: The TyG index is significantly and independently associated with the severity of NAFLD in obese patients. As a simple and non-invasive marker, it may serve as a useful tool for early screening and risk stratification of severe NAFLD in clinical practice.